Page 46 - AN-3-4

Advanced Neurology Anticoagulants as neuroprotective therapeutics

USA. 2021;118(33):e2102191118. brain disorders and target of rapidly evolving therapeutic
strategies. Science. 2021;371(6532):eabb8255.
doi: 10.1073/pnas.2102191118
61. Hultman K, Strickland S, Norris EH. The APOE e4/e4 doi: 10.1126/science.abb8255
genotype potentiates vascular fibrin(ogen) deposition in 72. Chen X, Firulyova M, Manis M, et al. Microglia-mediated
amyloid-laden vessels in the brains of Alzheimer’s disease T cell infiltration drives neurodegeneration in tauopathy.
patients. J Cerebral Blood Flow Metab. 2013;33(8):1251-1258. Nature. 2023;615(7953):668-677.
doi: 10.1038/jcbfm.2013.76 doi: 10.1038/s41586-023-05788-0
62. Parhizkar S, Arzberger T, Brendel M, et al. Loss of TREM2 73. He Z, Guo JL, McBridge JD, et al. Amyloid-β plaques enhance
function increases amyloid seeding but reduces plaque- Alzheimer’s brain tau-seeded pathologies by facilitating
associated ApoE. Nat Neurosci. 2019,22(2):191-204. neuritic plaque tau aggregation. Nat Med. 2018;241:29-38.
doi: 10.1038/s41593-018-0296-9 doi: 10.1038/nm.4443
63. Schoch KM, Ezerskiy LA, Morhaus MM, et al. Acute Trem2 74. Aguilar-Pineda JA, Vera-Lopez KJ, Shrivastava P, et al.
reduction triggers increased microglial phagocytosis, Vascular smooth muscle cell dysfunction contribute to
slowing amyloid deposition in mice. Proc Natl Acad Sci USA. neuroinflammation and tau hyperphosphorylation in
2021;118(27):e2100356118. Alzheimer disease. Science. 2021;24(9):102993.
doi: 10.1073/pnas.2100356118 doi: 10.1016/j.isci.2021.102993
64. Korte N, Nortley, R, Attwell D. Cerebral blood flow decrease 75. Kim YA, Mellen M, Kizil C, Santa-Maria I. Mechanisms
as an early pathological mechanism in Alzheimer’s disease. linking cerebrovascular dysfunction and tauopathy:
Acta Neuropath. 2020;140(6):793-810. Adding a layer of epiregulatory complexity. Br J Pharmacol.
doi: 10.1007/s00401-020-02215-w 2024;181(6):879-895.
65. Jellinger KA. Alzheimer disease and cerebrovascular doi: 10.1111/bph.16280
pathology: An update. J Neural Transm (Vienna). 76. Onyango I, Jauregui GV, Carna M, Bennett JP Jr., Stokin GB.
2002;109(5-6):813-836. Neuroinflammation in Alzheimer’s disease. Biomedicines.
doi: 10.1007/s007020200068 2021;9(5):524.
66. Maier FC, Wehrl HF, Schmid AM, et al. Longitudinal PET- doi: 10.3390/biomedicines9050524
MRI reveals β-amyloid deposition and rCBF dynamics 77. Grammas P, Samany PG, Thirumangalakudi L. Thrombin
and connects vascular amyloidosis to quantitative loss of and inflammatory proteins are elevated in Alzheimer’s
perfusion. Nat Med. 2014;20(12):1485-1492. disease microvessels: Implications for disease pathogenesis.
doi: 10.1038/nm.3734 J Alzheimers Dis. 2006;9(1):51-58.
67. Eisele YS, Obermüller U, Heilbronner G, et al. Peripherally doi: 10.3233/jad-2006-9105
applied Abeta-containing inoculates induce cerebral beta- 78. BartelsT, De Schepper S, Hong S. Microglia modulate
amyloidosis. Science. 2010;330(6006):980-982. neurodegeneration in Alzheimer’s and Parkinson’s diseases.
doi: 10.1126/science.1194516 Science. 2020;370(6512):66-69.
68. Sevigny J, Chiao P, Bussiere T, et al. The antibody doi: 10.1126/science.abb8587
aducanumab reduces Aβ plaques in Alzheimer’s disease. 79. Butler CA, Popescu AS, Kitchener EJ, Allendorf DH,
Nature. 2016;537(7618):50-56. Puigdellivol M, Brown GC. Microglial phagocytosis
doi: 10.1038/nature19323 of neurons in neurodegeneration, and its regulation.
J Neurochem. 2021;158(3):621-639.
69. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early
symptomatic Alzheimer disease: The TRAILBLAZER-ALZ doi: 10.1111/jnc.15327
2 randomized clinical trial. JAMA. 2023;330(6):512-527. 80. Kim SK, Sharma C, Jung UJ, Kim SR. Pathophysiological role
doi: 10.1001/jama.2023.13239 of microglial activation induced by blood-borne proteins in
Alzheimer’s disease. Biomedicines. 2023;11(5):1383.
70. Vukmir RB. Amyloid-related imaging abnormalities (ARIA):
Diagnosis, management, and care in the setting of amyloid- doi: 10.3390/biomedicines11051383
modifying therapy. Ann Clin Transl Neurol. 2024;11:1669- 81. Venegas C, Kumar S, Franklin BS, et al. Microglia-derived
1680. ASC specks cross-seed amyloid-β in Alzheimer’s disease.
doi: 10.1002/acn3.52042 Nature. 2017;552(7685):355-361.
71. Chang CW, Shao E, Mucke L. Tau: Enabler of diverse doi: 10.1038/nature25158

Volume 3 Issue 4 (2024) 28 doi: 10.36922/an.3799